Keywords: xenova, sees, sharp, increase, loss, administration, costs

Xenova sees sharp increase in loss as R&D, administration costs escalate

Article | 20 November 2001

• Print This

UK vaccines and cancer drug development specialist Xenova has reportedsales of $1.1 million for the third quarter of 2001, with the loss ...

Enjoying this article? To continue reading you need to login or subscribe.